title: Kidney preservation with IGL-1 solution: a preliminary report.
abstract: The University of Wisconsin (UW) solution is the most commonly used preservation solution. However, a new preservation solution-IGL-1-contains an inversion of K and Na concentrations and substitution of polyethylene glycol for hydroxyethyl starch in the UW solution. The present study is the first clinical experience on the outcome of kidneys preserved in IGL-1 solution. From June 2003 to June 2004, 119 cadaveric kidneys were retrieved and stored in IGL-1 solutions; among the 119 organs, this study includes 37 IGL-1-preserved kidneys that were locally transplanted versus 33 kidneys stored in University of Wisconsin (UW) solution that were also locally transplanted. The groups were comparable with regard to donor and recipient characteristics. Renal function outcome was evaluated by comparing delayed graft function (DGF) rates, the evolution of serum creatinine, daily urine output, and creatinine clearance. Biopsies were performed after reperfusion to evaluate apoptosis. The incidence of DGF was 5.71% among IGL-1 kidneys and 13.79% among UW kidneys. Creatinine values were significantly lower among the IGL-1 group from 2 to 14 days postoperative and at 1 month. Daily urinary output did not show any significant differences between the two groups. IGL-1 kidneys had a superior creatinine clearance during the first 15 postoperative days compared to UW kidneys. Kidneys preserved in IGL-1 solution showed fewer apoptotic cells compared to kidneys preserved in UW solution. This preliminary report suggests a superiority of IGL-1 for the immediate outcome of transplanted kidneys.
authors.affiliation: Service de Chirurgie et Medicine de la Transplantation, Hopital Edouard Herriot, Lyon, France.
authors.forename: L
authors.initials: L
authors.lastname: Badet
authors.forename: P
authors.initials: P
authors.lastname: Petruzzo
authors.forename: N
authors.initials: N
authors.lastname: Lefrançois
authors.forename: B
authors.initials: B
authors.lastname: McGregor
authors.forename: M
authors.initials: M
authors.lastname: Espa
authors.forename: C
authors.initials: C
authors.lastname: Berthillot
authors.forename: F
authors.initials: F
authors.lastname: Danjou
authors.forename: P
authors.initials: P
authors.lastname: Contu
authors.forename: A H
authors.initials: AH
authors.lastname: Aissa
authors.forename: S R
authors.initials: SR
authors.lastname: Virieux
authors.forename: J J
authors.initials: JJ
authors.lastname: Colpart
authors.forename: X
authors.initials: X
authors.lastname: Martin
mesh_terms: D000241:Adenosine; D000328:Adult; D000493:Allopurinol; D002102:Cadaver; D005260:Female; D005978:Glutathione; D006801:Humans; D007328:Insulin; D007668:Kidney; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D019188:Organ Preservation Solutions; D011092:Polyethylene Glycols; D011188:Potassium; D011887:Raffinose; D012964:Sodium; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: C504757:IGL-1 solution; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D011092:Polyethylene Glycols; D000493:Allopurinol; D012964:Sodium; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose; D011188:Potassium